Whole pelvis radiation improves cancer-specific and overall survival in muscle-invasive bladder cancer compared to bladder-only radiation. Median cancer-specific survival was 84 months for whole ...

Patients with locally advanced muscle-invasive bladder cancer may benefit from dose-dense gemcitabine and cisplatin. The treatment of preoperative dose-dense gemcitabine and cisplatin chemotherapies ...

Durvalumab plus gemcitabine and cisplatin significantly improved event free survival and overall survival compared with gemcitabine and cisplatin. The Food and Drug Administration (FDA) has approved ...

The durvalumab arm showed a 32% decrease in the risk of disease progression, recurrence, not undergoing radical cystectomy, or death and a 25% reduction in the risk of death compared with the ...

Using multiparametric MRI (mpMRI) before surgery reduced time to correct treatment by 45 days for patients with muscle invasive bladder cancer. The imaging procedure was successful for over 92% of ...

Credit: Thinkstock Investigators conducted a network meta-analysis of phase 3 trials on MIBC treatments to provide comparative ranking of perioperative therapies. Findings from studies over 30 years ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved pembrolizumab or pembrolizumab and berahyaluronidase alfa-pmph in combination with enfortumab ...

Most people with bladder cancer begin treatment by having surgery to remove their cancer. If bladder cancer has spread beyond your bladder, you might have chemotherapy first. This can help treat ...

Patients with localized muscle-invasive bladder cancer (MIBC) who received radiation plus the immune checkpoint inhibitors (ICIs) durvalumab (Imfinzi) and tremelimumab (Imjudo) had durable responses ...

The extent of the bladder cancer — how far it has spread — matters. Your care team needs to know if your cancer sits on or in the first lining of your bladder (non-muscle invasive), if it goes into ...

Overall survival is no better for patients diagnosed with NMIBC who progress directly to metastasis. Survival is comparably poor for patients who develop metastases directly after non-muscle invasive ...